These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24157306)

  • 1. Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission.
    Meredith LW; Zitzmann N; McKeating JA
    Antiviral Res; 2013 Dec; 100(3):636-9. PubMed ID: 24157306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
    Griffin S; Stgelais C; Owsianka AM; Patel AH; Rowlands D; Harris M
    Hepatology; 2008 Dec; 48(6):1779-90. PubMed ID: 18828153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels.
    Breitinger U; Farag NS; Ali NKM; Ahmed M; El-Azizi MA; Breitinger HG
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33709903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the inhibitory mechanism of BIT225 drug against p7 viroporin using computational study.
    Behmard E; Abdolmaleki P; Taghdir M
    Biophys Chem; 2018 Feb; 233():47-54. PubMed ID: 29169687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.
    Breitinger U; Farag NS; Ali NKM; Breitinger HA
    Biophys J; 2016 Jun; 110(11):2419-2429. PubMed ID: 27276260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
    Wozniak AL; Griffin S; Rowlands D; Harris M; Yi M; Lemon SM; Weinman SA
    PLoS Pathog; 2010 Sep; 6(9):e1001087. PubMed ID: 20824094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro.
    Haqshenas G; Dong X; Ewart G; Bowden S; Gowans EJ
    Virology; 2007 Mar; 360(1):17-26. PubMed ID: 17097709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.
    Mathew S; Fatima K; Fatmi MQ; Archunan G; Ilyas M; Begum N; Azhar E; Damanhouri G; Qadri I
    PLoS One; 2015; 10(6):e0126510. PubMed ID: 26030803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amino-terminus of the hepatitis C virus (HCV) p7 viroporin and its cleavage from glycoprotein E2-p7 precursor determine specific infectivity and secretion levels of HCV particle types.
    Denolly S; Mialon C; Bourlet T; Amirache F; Penin F; Lindenbach B; Boson B; Cosset FL
    PLoS Pathog; 2017 Dec; 13(12):e1006774. PubMed ID: 29253880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy.
    Shaw J; Gosain R; Kalita MM; Foster TL; Kankanala J; Mahato DR; Abas S; King BJ; Scott C; Brown E; Bentham MJ; Wetherill L; Bloy A; Samson A; Harris M; Mankouri J; Rowlands DJ; Macdonald A; Tarr AW; Fischer WB; Foster R; Griffin S
    Elife; 2020 Nov; 9():. PubMed ID: 33169665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor Development against p7 Channel in Hepatitis C Virus.
    Wei S; Hu X; Du L; Zhao L; Xue H; Liu C; Chou JJ; Zhong J; Tong Y; Wang S; OuYang B
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33802584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System.
    Zhao F; Zhao T; Deng L; Lv D; Zhang X; Pan X; Xu J; Long G
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27852847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?
    Griffin S
    Future Med Chem; 2014; 6(17):1893-907. PubMed ID: 25495983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Study of HCV p7 Channel: Insight into a New Strategy for HCV Inhibitor Design.
    Ying B; Pang S; Yang J; Zhong Y; Wang J
    Interdiscip Sci; 2019 Jun; 11(2):292-299. PubMed ID: 30194627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.
    Foster TL; Thompson GS; Kalverda AP; Kankanala J; Bentham M; Wetherill LF; Thompson J; Barker AM; Clarke D; Noerenberg M; Pearson AR; Rowlands DJ; Homans SW; Harris M; Foster R; Griffin S
    Hepatology; 2014 Feb; 59(2):408-22. PubMed ID: 24022996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity.
    Aligeti M; Roder A; Horner SM
    J Virol; 2015 Nov; 89(22):11523-33. PubMed ID: 26355084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences.
    Atkins E; Tatineni R; Li H; Gretch D; Harris M; Griffin S
    Virology; 2014 Jan; 448():117-24. PubMed ID: 24314642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
    Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
    Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and Functional Properties of the Hepatitis C Virus p7 Viroporin.
    Madan V; Bartenschlager R
    Viruses; 2015 Aug; 7(8):4461-81. PubMed ID: 26258788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.